Advanced Medical Solutions Group shares plunged 14.91% following an announcement on Friday, May 15 that funds affiliated with TA Associates would not be submitting a formal offer for the company’s entire issued share capital. The confirmation ended a formal offer period that had been opened after a prior disclosure in April.
On April 18, 2026 AMS revealed that funds linked to TA Associates were considering a possible proposal for the whole of the issued and to be issued share capital. That disclosure placed the healthcare products maker into a formal offer period under the UK Takeover Code and set a deadline of May 16 for TA Associates either to table a firm bid or to withdraw.
The decision by TA Associates to step back is not the first instance of takeover interest evaporating for AMS. In March 2025, the group attracted bid interest from Montagu Private Equity LLP, a London-based mid-market private equity firm, but that approach also did not materialise into a formal offer.
Market reaction was swift once it became clear the latest approach would not result in a takeover. Traders moved to remove the acquisition premium that had been priced into AMS shares since the April disclosure. Media reports had suggested TA Associates was preparing a 280-pence-per-share bid, a level that would have valued the company at more than A3600 million.
Broader market conditions offered a mixed backdrop on the same trading day. The FTSE 100 traded flat to slightly lower as investors weighed rising tensions in the Middle East and speculation about a potential challenge to Prime Minister Keir Starmer's leadership. The FTSE 250, where Advanced Medical Solutions is a constituent, declined 0.47% during the session.
The wider weakness followed a disappointing finish to trading last week. Analysts and market participants pointed to losses in global bond markets, higher energy prices, and renewed domestic political uncertainty as factors continuing to exert downward pressure on investor sentiment.
With the potential bid no longer on the table, the immediate impact on AMS equity reflects the removal of takeover expectations. The stock's sharp move underscores how prospective acquisition activity can influence mid-cap valuations and the sensitivity of such names to confirmed deal signals.